ANL vs NRIX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NRIX Captures Institutional Edge (2โ2 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nurix Therapeutics, Inc. Common stock (NRIX) driven by superior Valuation, Growth & Margin while ANL counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, ANL trades at N/M Forward P/E with -123.5% operating margin (+178.1% YoY revenue) versus NRIX at N/M Forward P/E and 41.3% operating margin (+8426.3% YoY). In options structure, ANL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against NRIX sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ANL | NRIX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $677.5M | $1.7B | Larger Scale | NRIX |
| Trailing P/E Ratio Valuation | N/M | 6.4x | Lower Multiple | NRIX |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +178.1% | +8426.3% | Higher Growth | NRIX |
| Operating Margin (TTM) Profitability | -123.5% | 41.3% | Higher Margin | NRIX |
| Net Profit Margin Profitability | -124.8% | 42.0% | Higher Margin | NRIX |
| Return on Equity (ROE) Capital Efficiency | -20.2% | 44.0% | Higher ROE | NRIX |
| 52-Week Range Position Momentum | 56% ($1โ$17) | 18% ($12โ$28) | Stronger Trend | ANL |
| Beta / 30D Volatility Risk Regime | 2.61ฮฒ ยท 79% Vol | 0.94ฮฒ ยท 141% Vol | Lower Realized Risk | ANL |
| Unified Institutional Score Composite Signal | 48.3 / 100 (HOLD) | 51.5 / 100 (HOLD) | Higher Composite | NRIX |